Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma
The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM) is a rare orphan disease associated with prior exposure...
Saved in:
| Published in | BMC pulmonary medicine Vol. 21; no. 1; pp. 148 - 24 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
05.05.2021
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM) is a rare orphan disease associated with prior exposure to asbestos, with a dismal prognosis. Evidence from clinical trials of checkpoint inhibitors in this rare disease, suggest that such therapies may play a role as a treatment option for a proportion of patients with this cancer.
While the majority of studies currently focus on the established checkpoint inhibitors (CTLA4 and PD1/PDL1), there are many other potential checkpoints that could also be targeted. In this review I provide a synopsis of current clinical trials of immunotherapies in MPM, explore potential candidate new avenues that may become future targets for immunotherapy and discuss aspects of immunotherapy that may affect the clinical outcomes of such therapies in this cancer.
The current situation regarding checkpoint inhibitors in the management of MPM whilst encouraging, despite impressive durable responses, immune checkpoint inhibitors do not provide a long-term benefit to the majority of patients with cancer. Additional studies are therefore required to further delineate and improve our understanding of both checkpoint inhibitors and the immune system in MPM. Moreover, many new potential checkpoints have yet to be studied for their therapeutic potential in MPM. All these plus the existing checkpoint inhibitors will require the development of new biomarkers for patient stratification, response and also for predicting or monitoring the emergence of resistance to these agents in MPM patients. Other potential therapeutic avenues such CAR-T therapy or treatments like oncolytic viruses or agents that target the interferon pathway designed to recruit more immune cells to the tumor also hold great promise in this hard to treat cancer. |
|---|---|
| AbstractList | Abstract Background The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM) is a rare orphan disease associated with prior exposure to asbestos, with a dismal prognosis. Evidence from clinical trials of checkpoint inhibitors in this rare disease, suggest that such therapies may play a role as a treatment option for a proportion of patients with this cancer. Main text While the majority of studies currently focus on the established checkpoint inhibitors (CTLA4 and PD1/PDL1), there are many other potential checkpoints that could also be targeted. In this review I provide a synopsis of current clinical trials of immunotherapies in MPM, explore potential candidate new avenues that may become future targets for immunotherapy and discuss aspects of immunotherapy that may affect the clinical outcomes of such therapies in this cancer. Conclusions The current situation regarding checkpoint inhibitors in the management of MPM whilst encouraging, despite impressive durable responses, immune checkpoint inhibitors do not provide a long-term benefit to the majority of patients with cancer. Additional studies are therefore required to further delineate and improve our understanding of both checkpoint inhibitors and the immune system in MPM. Moreover, many new potential checkpoints have yet to be studied for their therapeutic potential in MPM. All these plus the existing checkpoint inhibitors will require the development of new biomarkers for patient stratification, response and also for predicting or monitoring the emergence of resistance to these agents in MPM patients. Other potential therapeutic avenues such CAR-T therapy or treatments like oncolytic viruses or agents that target the interferon pathway designed to recruit more immune cells to the tumor also hold great promise in this hard to treat cancer. Background The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM) is a rare orphan disease associated with prior exposure to asbestos, with a dismal prognosis. Evidence from clinical trials of checkpoint inhibitors in this rare disease, suggest that such therapies may play a role as a treatment option for a proportion of patients with this cancer. Main text While the majority of studies currently focus on the established checkpoint inhibitors (CTLA4 and PD1/PDL1), there are many other potential checkpoints that could also be targeted. In this review I provide a synopsis of current clinical trials of immunotherapies in MPM, explore potential candidate new avenues that may become future targets for immunotherapy and discuss aspects of immunotherapy that may affect the clinical outcomes of such therapies in this cancer. Conclusions The current situation regarding checkpoint inhibitors in the management of MPM whilst encouraging, despite impressive durable responses, immune checkpoint inhibitors do not provide a long-term benefit to the majority of patients with cancer. Additional studies are therefore required to further delineate and improve our understanding of both checkpoint inhibitors and the immune system in MPM. Moreover, many new potential checkpoints have yet to be studied for their therapeutic potential in MPM. All these plus the existing checkpoint inhibitors will require the development of new biomarkers for patient stratification, response and also for predicting or monitoring the emergence of resistance to these agents in MPM patients. Other potential therapeutic avenues such CAR-T therapy or treatments like oncolytic viruses or agents that target the interferon pathway designed to recruit more immune cells to the tumor also hold great promise in this hard to treat cancer. The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM) is a rare orphan disease associated with prior exposure to asbestos, with a dismal prognosis. Evidence from clinical trials of checkpoint inhibitors in this rare disease, suggest that such therapies may play a role as a treatment option for a proportion of patients with this cancer.BACKGROUNDThe role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM) is a rare orphan disease associated with prior exposure to asbestos, with a dismal prognosis. Evidence from clinical trials of checkpoint inhibitors in this rare disease, suggest that such therapies may play a role as a treatment option for a proportion of patients with this cancer.While the majority of studies currently focus on the established checkpoint inhibitors (CTLA4 and PD1/PDL1), there are many other potential checkpoints that could also be targeted. In this review I provide a synopsis of current clinical trials of immunotherapies in MPM, explore potential candidate new avenues that may become future targets for immunotherapy and discuss aspects of immunotherapy that may affect the clinical outcomes of such therapies in this cancer.MAIN TEXTWhile the majority of studies currently focus on the established checkpoint inhibitors (CTLA4 and PD1/PDL1), there are many other potential checkpoints that could also be targeted. In this review I provide a synopsis of current clinical trials of immunotherapies in MPM, explore potential candidate new avenues that may become future targets for immunotherapy and discuss aspects of immunotherapy that may affect the clinical outcomes of such therapies in this cancer.The current situation regarding checkpoint inhibitors in the management of MPM whilst encouraging, despite impressive durable responses, immune checkpoint inhibitors do not provide a long-term benefit to the majority of patients with cancer. Additional studies are therefore required to further delineate and improve our understanding of both checkpoint inhibitors and the immune system in MPM. Moreover, many new potential checkpoints have yet to be studied for their therapeutic potential in MPM. All these plus the existing checkpoint inhibitors will require the development of new biomarkers for patient stratification, response and also for predicting or monitoring the emergence of resistance to these agents in MPM patients. Other potential therapeutic avenues such CAR-T therapy or treatments like oncolytic viruses or agents that target the interferon pathway designed to recruit more immune cells to the tumor also hold great promise in this hard to treat cancer.CONCLUSIONSThe current situation regarding checkpoint inhibitors in the management of MPM whilst encouraging, despite impressive durable responses, immune checkpoint inhibitors do not provide a long-term benefit to the majority of patients with cancer. Additional studies are therefore required to further delineate and improve our understanding of both checkpoint inhibitors and the immune system in MPM. Moreover, many new potential checkpoints have yet to be studied for their therapeutic potential in MPM. All these plus the existing checkpoint inhibitors will require the development of new biomarkers for patient stratification, response and also for predicting or monitoring the emergence of resistance to these agents in MPM patients. Other potential therapeutic avenues such CAR-T therapy or treatments like oncolytic viruses or agents that target the interferon pathway designed to recruit more immune cells to the tumor also hold great promise in this hard to treat cancer. The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM) is a rare orphan disease associated with prior exposure to asbestos, with a dismal prognosis. Evidence from clinical trials of checkpoint inhibitors in this rare disease, suggest that such therapies may play a role as a treatment option for a proportion of patients with this cancer. The current situation regarding checkpoint inhibitors in the management of MPM whilst encouraging, despite impressive durable responses, immune checkpoint inhibitors do not provide a long-term benefit to the majority of patients with cancer. Additional studies are therefore required to further delineate and improve our understanding of both checkpoint inhibitors and the immune system in MPM. Moreover, many new potential checkpoints have yet to be studied for their therapeutic potential in MPM. All these plus the existing checkpoint inhibitors will require the development of new biomarkers for patient stratification, response and also for predicting or monitoring the emergence of resistance to these agents in MPM patients. Other potential therapeutic avenues such CAR-T therapy or treatments like oncolytic viruses or agents that target the interferon pathway designed to recruit more immune cells to the tumor also hold great promise in this hard to treat cancer. The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM) is a rare orphan disease associated with prior exposure to asbestos, with a dismal prognosis. Evidence from clinical trials of checkpoint inhibitors in this rare disease, suggest that such therapies may play a role as a treatment option for a proportion of patients with this cancer. While the majority of studies currently focus on the established checkpoint inhibitors (CTLA4 and PD1/PDL1), there are many other potential checkpoints that could also be targeted. In this review I provide a synopsis of current clinical trials of immunotherapies in MPM, explore potential candidate new avenues that may become future targets for immunotherapy and discuss aspects of immunotherapy that may affect the clinical outcomes of such therapies in this cancer. The current situation regarding checkpoint inhibitors in the management of MPM whilst encouraging, despite impressive durable responses, immune checkpoint inhibitors do not provide a long-term benefit to the majority of patients with cancer. Additional studies are therefore required to further delineate and improve our understanding of both checkpoint inhibitors and the immune system in MPM. Moreover, many new potential checkpoints have yet to be studied for their therapeutic potential in MPM. All these plus the existing checkpoint inhibitors will require the development of new biomarkers for patient stratification, response and also for predicting or monitoring the emergence of resistance to these agents in MPM patients. Other potential therapeutic avenues such CAR-T therapy or treatments like oncolytic viruses or agents that target the interferon pathway designed to recruit more immune cells to the tumor also hold great promise in this hard to treat cancer. |
| ArticleNumber | 148 |
| Audience | Academic |
| Author | Gray, Steven G. |
| Author_xml | – sequence: 1 givenname: Steven G. orcidid: 0000-0002-5850-6392 surname: Gray fullname: Gray, Steven G. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33952230$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktr3TAQhU1JaR7tH-iiGLrpxqlGsiV5UwghbQKBbtpuhSxLji6WdCvbgfz7jnOTNDeUYpD1OPOJMzrHxUFM0RbFeyCnAJJ_noDKllSEQkWgAVaJV8UR1AIqWnN-8Gx-WBxP04YQELJhb4pDxtqGUkaOil8XwebBx6HUtzYudip9LH0IS0zzjc16e1e6lEucl0FHPdhg41wmh6vRD1HjYjvaJeuxDHZaa0afgn5bvHZ6nOy7h_9J8fPrxY_zy-r6-7er87PryjSczZUjxsneMUPqFohhrqaNFdIIwUWHBx1rXWfamjWmEc5wV-PYOSB9awy6YyfF1Y7bJ71R2-yDzncqaa_uN1IelM6zN6NVrewRIp0hQOragtYaGl4bojuiJQFkfdmxtksXbG_QKNrag-6fRH-jhnSrJGmFpBwBnx4AOf3GVs4q-MnYcdTRpmVSFHvOKQBQlH58Id2kJUds1aqSbSNazv-qBo0GfHQJ7zUrVJ1xDjVjjVxZp_9Q4dfb4A1Gxnnc3yv48Nzok8PHVKCA7gQmp2nK1j1JgKg1emoXPYXRU_fRU-tTyBdFxs969mltlh__V_oHdOjdDQ |
| CitedBy_id | crossref_primary_10_1016_j_jtho_2024_01_016 crossref_primary_10_1016_j_opresp_2024_100323 crossref_primary_10_1186_s13020_024_00904_2 crossref_primary_10_3389_fonc_2023_1259314 crossref_primary_10_1136_jitc_2021_003543 crossref_primary_10_1016_j_resinv_2024_12_017 crossref_primary_10_1016_j_cpccr_2022_100138 crossref_primary_10_2147_LCTT_S288535 crossref_primary_10_3389_fimmu_2023_1121557 crossref_primary_10_3390_ijms22169014 crossref_primary_10_3390_cancers15112940 crossref_primary_10_1080_14656566_2022_2072211 crossref_primary_10_1038_s41698_024_00531_y crossref_primary_10_3390_ijerph192214763 crossref_primary_10_1016_j_lungcan_2021_11_001 crossref_primary_10_1186_s12885_021_08980_5 crossref_primary_10_3390_cancers15245808 crossref_primary_10_1186_s12885_023_11636_1 crossref_primary_10_1016_j_adro_2022_101013 crossref_primary_10_3389_fonc_2023_1285031 crossref_primary_10_3390_cancers13133338 |
| Cites_doi | 10.1016/S1470-2045(18)30868-4 10.1007/s11864-020-00807-y 10.1158/1078-0432.CCR-17-1117 10.1038/mt.2009.309 10.1016/S0169-5002(01)00250-1 10.1016/j.ebiom.2019.09.003 10.1080/14712598.2020.1703945 10.1158/1078-0432.CCR-19-1836 10.1016/S1470-2045(20)30433-2 10.1016/S2213-2600(18)30420-X 10.1016/j.jtho.2019.03.029 10.1038/nm.3947 10.1097/00002371-199809000-00007 10.1080/2162402X.2017.1363137 10.1016/j.jtho.2017.09.001 10.2217/imt-2016-0141 10.1200/JCO.2020.38.15_suppl.TPS9078 10.1080/2162402X.2018.1466018 10.2217/fon-2017-0307 10.1016/j.cllc.2020.11.009 10.1200/JCO.2020.38.15_suppl.9003 10.1016/S1470-2045(17)30169-9 10.1586/ers.10.33 10.1158/1078-0432.CCR-11-0351 10.3892/ijmm.2012.1138 10.1016/j.jtho.2017.10.001 10.3390/cancers11121953 10.1001/jamaoncol.2019.0446 10.1158/1078-0432.CCR-13-0458 10.1007/s40259-020-00425-y 10.1016/j.jtho.2019.03.030 10.1016/j.ctrv.2020.102084 10.1080/14737140.2020.1745067 10.1093/intimm/dxs005 10.1016/j.lungcan.2008.04.001 10.1158/1078-0432.CCR-19-0103 10.1016/S2213-2600(18)30151-6 10.1038/468884a 10.1016/j.bbcan.2020.188386 10.1001/jamanetworkopen.2020.25109 10.1177/2036361319863498 10.1158/1078-0432.CCR-19-2379 10.1164/rccm.200909-1465OC 10.1136/jitc-2019-000251 10.3390/ijms21218305 10.1016/S1470-2045(20)30445-9 10.1016/j.jtho.2021.01.323 10.1186/1479-5876-11-187 10.1200/JCO.2019.37.15_suppl.8549 10.1186/s12995-020-00267-y 10.1016/j.ccr.2011.12.029 10.3389/fonc.2020.554570 10.1158/1078-0432.CCR-18-2641 10.1038/s41379-019-0364-z 10.1038/s41423-019-0245-x 10.1016/j.ymthe.2020.10.023 10.1126/science.aax0182 10.1158/1078-0432.CCR-15-2133 10.1136/jitc-2020-000713 10.1016/S1470-2045(19)30828-9 10.1016/j.cllc.2020.10.005 10.18632/oncotarget.6285 10.3322/caac.21572 10.21037/tlcr-19-686 10.3390/ijms20020429 10.1016/S1470-2045(18)30765-4 10.1016/j.annonc.2020.09.009 10.3389/fonc.2020.00126 10.1016/j.thorsurg.2020.08.003 10.21037/tlcr.2019.11.23 10.1038/nbt.4195 10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N 10.3389/fimmu.2018.02909 10.1200/JCO.1996.14.3.878 10.1093/ejcts/ezaa158 10.1164/rccm.201103-0554CR 10.1200/JCO.2020.38.15_suppl.3071 10.1016/j.jtho.2018.08.2036 10.1080/2162402X.2016.1261241 10.1016/j.canlet.2017.02.015 10.1016/S1470-2045(19)30831-9 10.1016/S1470-2045(17)30446-1 10.1080/14712598.2019.1606209 10.1016/j.jtho.2021.01.308 10.1038/nm.3909 10.1186/s13046-020-1536-x 10.1016/S1470-2045(19)30829-0 10.1136/jitc-2020-001486 10.3390/cancers12071826 10.1200/JCO.2017.76.6394 10.1002/1878-0261.12651 10.1158/1078-0432.CCR-18-1231 10.1016/j.jtho.2019.04.029 10.1016/j.cellbi.2008.10.011 10.1038/ng.3520 10.1016/j.ebiom.2020.103040 10.1016/j.jtho.2018.08.277 10.1186/s40425-018-0454-3 10.1002/cncr.31997 10.1016/j.jtho.2016.11.1522 10.18632/oncotarget.23169 10.1136/jitc-2020-000957 10.1378/chest.121.6.1921 10.1038/s41467-019-09307-6 10.3181/00379727-136-35454 10.1186/s13148-018-0517-9 10.1016/S1470-2045(20)30462-9 10.1080/23723556.2019.1610322 10.1016/j.imlet.2020.04.002 10.1073/pnas.1105887108 10.1016/j.humpath.2016.01.010 10.1016/j.ctrv.2015.09.006 10.1038/s41591-019-0382-x 10.3390/cancers13020282 10.1164/rccm.201512-2444ED 10.2967/jnumed.120.250720 10.3390/cancers9090115 10.1016/j.omto.2019.02.001 10.1200/JCO.2020.38.15_suppl.3004 10.1126/scitranslmed.3010162 10.4049/jimmunol.0803826 10.1007/s10147-013-0619-5 10.1111/crj.13010 10.1016/j.jtho.2018.05.038 10.1016/j.jtho.2020.05.019 10.1158/2326-6066.CIR-16-0171 10.1158/2326-6066.CIR-14-0039 10.1002/1097-0142(20010801)92:3<650::AID-CNCR1366>3.0.CO;2-0 10.1080/2162402X.2018.1494111 10.1158/1078-0432.CCR-17-3757 10.1111/pin.13028 10.1016/j.neo.2017.05.002 10.1136/jitc-2020-000911 10.1016/j.lungcan.2020.09.026 10.1200/JCO.2003.11.136 10.1158/1078-0432.CCR-17-2522 10.1007/s11864-019-0613-x 10.1164/rccm.201508-1573OC 10.1093/oxfordjournals.annonc.a058941 10.1593/neo.07112 10.2967/jnumed.120.245803 10.1158/1078-0432.CCR-18-3133 10.3390/ijms20112674 10.1016/j.lungcan.2006.01.007 10.18632/oncotarget.21113 10.1097/JTO.0b013e3181a8634d 10.1136/oemed-2016-104173 10.21037/tlcr.2019.05.05 10.1038/s41379-019-0328-3 10.1200/EDBK_240837 10.1200/JCO.2018.78.2276 10.1080/14728222.2020.1841750 10.1038/s41587-020-0666-1 10.1158/1078-0432.CCR-16-1741 10.1007/BF02303746 10.1200/JCO.2020.38.15_suppl.e15086 10.1172/jci.insight.128474 10.1001/jamaoncol.2018.5428 10.1158/2159-8290.CD-18-0367 10.1172/JCI83092 10.1158/2326-6066.CIR-15-0077-T 10.1146/annurev-immunol-041015-055435 10.1158/2159-8290.CD-18-0804 10.1016/j.ejcts.2006.11.046 10.1164/rccm.200501-057OC 10.1016/j.ctrv.2018.07.006 10.1111/bcp.14337 10.1002/jcp.22600 10.18632/oncotarget.1542 10.1016/j.jtho.2019.12.128 10.1016/S0002-9440(10)62492-3 10.1016/S0140-6736(20)32714-8 10.1016/S1470-2045(19)30642-4 10.1080/2162402X.2019.1638211 10.1002/jcp.22724 10.1136/jitc-2020-001014 10.1016/S0140-6736(15)01238-6 10.21037/tlcr-19-485 10.1111/j.1445-5994.1993.tb04727.x 10.1200/JCO.2020.38.15_suppl.9058 10.1158/1535-7163.MCT-19-0356 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 |
| Copyright_xml | – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12890-021-01513-7 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Acceso a contenido Full Text - Doaj |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2466 |
| EndPage | 24 |
| ExternalDocumentID | oai_doaj_org_article_98dc578fc01044e1aaa1564c0ab0a801 PMC8097826 A661433582 33952230 10_1186_s12890_021_01513_7 |
| Genre | Journal Article Review |
| GeographicLocations | Ireland |
| GeographicLocations_xml | – name: Ireland |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABUWG ACGFO ACGFS ACIHN ACPRK ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PMFND 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c563t-f0cf8df3c04910c3f425e78c7767b8dfb39fbc9435c57fc6f47fcbf10d9cc1473 |
| IEDL.DBID | DOA |
| ISSN | 1471-2466 |
| IngestDate | Wed Aug 27 01:28:35 EDT 2025 Thu Aug 21 14:07:36 EDT 2025 Fri Jul 11 08:25:43 EDT 2025 Fri Jul 25 22:30:37 EDT 2025 Tue Jun 17 20:54:58 EDT 2025 Tue Jun 10 20:54:16 EDT 2025 Thu Apr 03 06:57:25 EDT 2025 Thu Apr 24 23:07:03 EDT 2025 Tue Jul 01 02:40:25 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c563t-f0cf8df3c04910c3f425e78c7767b8dfb39fbc9435c57fc6f47fcbf10d9cc1473 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-5850-6392 |
| OpenAccessLink | https://doaj.org/article/98dc578fc01044e1aaa1564c0ab0a801 |
| PMID | 33952230 |
| PQID | 2528957966 |
| PQPubID | 44785 |
| PageCount | 24 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_98dc578fc01044e1aaa1564c0ab0a801 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8097826 proquest_miscellaneous_2522621112 proquest_journals_2528957966 gale_infotracmisc_A661433582 gale_infotracacademiconefile_A661433582 pubmed_primary_33952230 crossref_primary_10_1186_s12890_021_01513_7 crossref_citationtrail_10_1186_s12890_021_01513_7 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-05-05 |
| PublicationDateYYYYMMDD | 2021-05-05 |
| PublicationDate_xml | – month: 05 year: 2021 text: 2021-05-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC pulmonary medicine |
| PublicationTitleAlternate | BMC Pulm Med |
| PublicationYear | 2021 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | H Kim (1513_CR194) 2020; 86 A Desai (1513_CR64) 2018; 13 RA Belderbos (1513_CR68) 2021; 16 SG Gray (1513_CR174) 2012; 30 1513_CR94 1513_CR97 DA Fennell (1513_CR67) 2021; 16 1513_CR95 A Minchom (1513_CR151) 2020; 8 E Marcq (1513_CR81) 2017; 8 NJ Vogelzang (1513_CR12) 2003; 21 AK Nowak (1513_CR19) 2019; 19 I Monnet (1513_CR29) 2002; 121 S Popat (1513_CR186) 2019; 125 DH Sterman (1513_CR109) 2016; 22 RA Belderbos (1513_CR139) 2019; 8 DH Sterman (1513_CR111) 2010; 18 E Tompa (1513_CR10) 2017; 74 JE Stein (1513_CR189) 2020; 26 M Okada (1513_CR55) 2019; 25 R Cornelissen (1513_CR132) 2016; 193 PM Forde (1513_CR66) 2019; 20 1513_CR86 T Peikert (1513_CR136) 2016; 193 1513_CR84 HI Pass (1513_CR30) 1997; 4 MG Zauderer (1513_CR168) 2020; 38 M Jaderberg (1513_CR115) 2020; 8 A Okonska (1513_CR172) 2020; 19 N Alcala (1513_CR90) 2019; 48 G Zalcman (1513_CR13) 2016; 387 A Bibby (1513_CR73) 2019; 20 LM Sholl (1513_CR147) 2020; 15 E Alard (1513_CR127) 2020; 12 M Carbone (1513_CR6) 2012; 227 S Khanna (1513_CR37) 2018; 24 EK Moon (1513_CR120) 2011; 17 L Calabrò (1513_CR92) 2011; 226 GJ Gordon (1513_CR77) 2005; 166 EJ Mun (1513_CR140) 2018; 24 SL Topalian (1513_CR188) 2020; 367 C Boutin (1513_CR25) 1994; 74 MM Awad (1513_CR99) 2016; 4 C Achard (1513_CR112) 2015; 6 Y Yoshikawa (1513_CR157) 2020; 10 L Cantini (1513_CR69) 2020; 9 DH Sterman (1513_CR110) 2011; 184 N van Zandwijk (1513_CR4) 2020; 20 C Wang (1513_CR160) 2019; 13 SG Gray (1513_CR47) 2020; 9 WL Yan (1513_CR32) 2017; 9 DR Gomez (1513_CR41) 2019; 14 MB Barnet (1513_CR185) 2018; 13 N Macedo (1513_CR31) 2020; 8 C Wu (1513_CR83) 2019; 11 H Vroman (1513_CR138) 2020; 8 L Quetel (1513_CR156) 2020; 14 G Fromm (1513_CR108) 2018; 6 E Marcq (1513_CR85) 2021; 13 E Marcq (1513_CR80) 2015; 41 N Acharya (1513_CR98) 2020; 8 P Soulie (1513_CR27) 1996; 14 M Carbone (1513_CR5) 2011; 108 C Boutin (1513_CR24) 1990; 46 G Toyokawa (1513_CR191) 2014; 19 A Klampatsa (1513_CR125) 2017; 9 C Jackaman (1513_CR22) 2012; 24 M Bersanelli (1513_CR150) 2020; 21 T Thayaparan (1513_CR123) 2017; 6 T Maruhashi (1513_CR79) 2020; 8 T Delaunay (1513_CR113) 2020; 15 A Scherpereel (1513_CR70) 2019; 20 M Zauderer (1513_CR91) 2019; 7 J Hmeljak (1513_CR87) 2018; 8 J Fuentes-Antras (1513_CR183) 2018; 70 JS Friedberg (1513_CR40) 2019; 14 DS Chandrashekar (1513_CR78) 2017; 19 AK Nowak (1513_CR51) 2020; 21 GL Ceresoli (1513_CR144) 2020; 21 J Aerts (1513_CR137) 2018; 24 DM Woods (1513_CR161) 2015; 3 JP Hegmans (1513_CR135) 2010; 181 NK Brockwell (1513_CR195) 2020; 9 H Kindler (1513_CR46) 2017; 12 SC Wei (1513_CR44) 2018; 8 AL Frank (1513_CR3) 2020; 15 M Hamaidia (1513_CR169) 2019; 4 PA Ott (1513_CR61) 2019; 37 AK Nowak (1513_CR15) 2020; 10 MP Pistillo (1513_CR114) 2020; 17 R Hassan (1513_CR60) 2019; 5 LY Dirix (1513_CR33) 1994; 5 D Bensaid (1513_CR165) 2018; 10 M Barbarino (1513_CR143) 2020; 21 S Brosseau (1513_CR14) 2017; 13 G Buresti (1513_CR9) 2017; 108 S Kiesgen (1513_CR126) 2018; 13 S Champiat (1513_CR181) 2017; 23 JW Upham (1513_CR28) 1993; 23 A Marabelle (1513_CR106) 2020; 8 C Shao (1513_CR149) 2020; 3 A Klampatsa (1513_CR102) 2019; 8 KC Hicks (1513_CR163) 2018; 7 AK Field (1513_CR23) 1971; 136 HS Parra (1513_CR26) 2001; 92 MJ Disselhorst (1513_CR72) 2019; 7 JM Mankor (1513_CR74) 2020; 62 MP Kosty (1513_CR35) 2001; 34 N Fusco (1513_CR153) 2020; 150 VS Fear (1513_CR107) 2018; 7 HC Tsai (1513_CR159) 2012; 21 1513_CR117 M Wörnle (1513_CR177) 2009; 33 1513_CR116 1513_CR119 PC Schuberth (1513_CR122) 2013; 11 JP Hegmans (1513_CR134) 2005; 171 P Ehrlich (1513_CR16) 1909; 5 V Murthy (1513_CR20) 2019; 13 T Chen (1513_CR2) 2019; 5 YS Chung (1513_CR88) 2020; 33 SA Broomfield (1513_CR179) 2009; 182 Y Blum (1513_CR154) 2019; 6 Y Yang (1513_CR176) 2020; 223 1513_CR145 MG McNamara (1513_CR146) 2020; 89 T van den Ende (1513_CR45) 2020; 1874 AC Anderson (1513_CR96) 2014; 2 Y Blum (1513_CR155) 2019; 10 H Wang (1513_CR164) 2020; 39 PM Forde (1513_CR52) 2020; 38 JA Davidson (1513_CR34) 1998; 21 HL Kindler (1513_CR11) 2018; 36 M Terranova-Barberio (1513_CR162) 2017; 8 J Stebbing (1513_CR192) 2009; 63 LM LaFave (1513_CR166) 2015; 21 AS Mansfield (1513_CR56) 2019; 25 S Muller (1513_CR89) 2020; 33 1513_CR21 LB John (1513_CR129) 2013; 19 CJ de Gooijer (1513_CR142) 2020; 21 S Rafiq (1513_CR130) 2018; 36 L Calabrò (1513_CR71) 2018; 6 EW Alley (1513_CR62) 2017; 18 GW Stone (1513_CR178) 2009; 4 R Bueno (1513_CR148) 2016; 48 D Venkatraman (1513_CR75) 2019; 37 JE Reuss (1513_CR48) 2020; 18 1513_CR50 A Marabelle (1513_CR63) 2020; 21 1513_CR53 L Cherkassky (1513_CR131) 2016; 126 CM Fares (1513_CR175) 2019; 39 P Tallón de Lara (1513_CR170) 2018; 24 M Carbone (1513_CR1) 2019; 69 C Combaz-Lair (1513_CR180) 2016; 52 J Quispel-Janssen (1513_CR59) 2018; 13 DA Fennell (1513_CR141) 2019; 20 EP Borrelli (1513_CR190) 2021; 22 I Opitz (1513_CR39) 2020; 30 A Klampatsa (1513_CR124) 2017; 393 JM Chauvin (1513_CR101) 2020; 8 1513_CR152 AS Tsao (1513_CR38) 2018; 13 TE Keenan (1513_CR193) 2019; 25 1513_CR43 M Frelaut (1513_CR182) 2019; 20 JE Reuss (1513_CR49) 2020; 38 AJ Gentles (1513_CR105) 2015; 21 N Hosseinkhani (1513_CR118) 2020; 21 M Poorebrahim (1513_CR128) 2020; 8 C Aggarwal (1513_CR93) 2018; 6 E Marcq (1513_CR100) 2017; 6 S Popat (1513_CR58) 2020; 31 M Maio (1513_CR57) 2017; 18 A Powell (1513_CR36) 2006; 52 1513_CR187 E Dolgin (1513_CR103) 2020; 38 J Varadé (1513_CR17) 2020; 8 K Hotta (1513_CR65) 2020; 20 H Locy (1513_CR18) 2018; 9 DR Rhodes (1513_CR76) 2007; 9 J Wrangle (1513_CR158) 2013; 4 A Guazzelli (1513_CR171) 2019; 20 E Borrelli (1513_CR8) 2019; 11 MM Gounder (1513_CR167) 2019; 25 B Maher (1513_CR7) 2010; 468 1513_CR173 I Opitz (1513_CR42) 2020; 58 DA Rhodes (1513_CR104) 2016; 34 K Wright (1513_CR54) 2020; 34 M Frelaut (1513_CR184) 2020; 34 PS Adusumilli (1513_CR121) 2014; 6 IC Salaroglio (1513_CR82) 2019; 14 M Gregoire (1513_CR133) 2010; 4 |
| References_xml | – volume: 20 start-page: 172 issue: 2 year: 2019 ident: 1513_CR73 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30868-4 – volume: 22 start-page: 14 issue: 2 year: 2021 ident: 1513_CR190 publication-title: Curr Treat Options Oncol doi: 10.1007/s11864-020-00807-y – volume: 8 start-page: A386 issue: Suppl 3 year: 2020 ident: 1513_CR115 publication-title: J Immunother Cancer – volume: 24 start-page: 266 issue: 2 year: 2018 ident: 1513_CR140 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-1117 – volume: 18 start-page: 852 issue: 4 year: 2010 ident: 1513_CR111 publication-title: Mol Ther doi: 10.1038/mt.2009.309 – volume: 34 start-page: 289 issue: 2 year: 2001 ident: 1513_CR35 publication-title: Lung Cancer doi: 10.1016/S0169-5002(01)00250-1 – volume: 48 start-page: 191 year: 2019 ident: 1513_CR90 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2019.09.003 – volume: 20 start-page: 109 issue: 2 year: 2020 ident: 1513_CR65 publication-title: Expert Opin Biol Ther doi: 10.1080/14712598.2020.1703945 – volume: 25 start-page: 5438 issue: 18 year: 2019 ident: 1513_CR56 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-1836 – volume: 21 start-page: 1255 issue: 10 year: 2020 ident: 1513_CR150 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30433-2 – volume: 7 start-page: 260 issue: 3 year: 2019 ident: 1513_CR72 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(18)30420-X – volume: 14 start-page: 1458 issue: 8 year: 2019 ident: 1513_CR82 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2019.03.029 – volume: 21 start-page: 1344 issue: 11 year: 2015 ident: 1513_CR166 publication-title: Nat Med doi: 10.1038/nm.3947 – volume: 21 start-page: 389 issue: 5 year: 1998 ident: 1513_CR34 publication-title: J Immunother doi: 10.1097/00002371-199809000-00007 – volume: 6 start-page: e1363137 issue: 12 year: 2017 ident: 1513_CR123 publication-title: Oncoimmunology doi: 10.1080/2162402X.2017.1363137 – volume: 13 start-page: e1 issue: 1 year: 2018 ident: 1513_CR185 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2017.09.001 – volume: 9 start-page: 347 issue: 4 year: 2017 ident: 1513_CR32 publication-title: Immunotherapy doi: 10.2217/imt-2016-0141 – volume: 38 start-page: 9078 issue: 15 year: 2020 ident: 1513_CR49 publication-title: J Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.TPS9078 – volume: 7 start-page: e1466018 issue: 11 year: 2018 ident: 1513_CR163 publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1466018 – volume: 13 start-page: 2537 issue: 28 year: 2017 ident: 1513_CR14 publication-title: Future Oncol doi: 10.2217/fon-2017-0307 – ident: 1513_CR152 doi: 10.1016/j.cllc.2020.11.009 – volume: 38 start-page: 9003 issue: 15 year: 2020 ident: 1513_CR52 publication-title: J Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.9003 – volume: 18 start-page: 623 issue: 5 year: 2017 ident: 1513_CR62 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30169-9 – volume: 4 start-page: 311 issue: 3 year: 2010 ident: 1513_CR133 publication-title: Expert Rev Respir Med doi: 10.1586/ers.10.33 – volume: 17 start-page: 4719 issue: 14 year: 2011 ident: 1513_CR120 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-0351 – volume: 30 start-page: 1505 issue: 6 year: 2012 ident: 1513_CR174 publication-title: Int J Mol Med doi: 10.3892/ijmm.2012.1138 – volume: 13 start-page: 16 issue: 1 year: 2018 ident: 1513_CR126 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2017.10.001 – volume: 11 start-page: 12 year: 2019 ident: 1513_CR83 publication-title: Cancers (Basel). doi: 10.3390/cancers11121953 – volume: 5 start-page: 779 issue: 6 year: 2019 ident: 1513_CR2 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2019.0446 – volume: 19 start-page: 5636 issue: 20 year: 2013 ident: 1513_CR129 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-0458 – volume: 34 start-page: 463 issue: 4 year: 2020 ident: 1513_CR184 publication-title: BioDrugs doi: 10.1007/s40259-020-00425-y – volume: 14 start-page: 1172 issue: 7 year: 2019 ident: 1513_CR41 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2019.03.030 – volume: 89 start-page: 102084 year: 2020 ident: 1513_CR146 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2020.102084 – volume: 20 start-page: 271 issue: 4 year: 2020 ident: 1513_CR4 publication-title: Expert Rev Anticancer Ther doi: 10.1080/14737140.2020.1745067 – volume: 24 start-page: 357 issue: 6 year: 2012 ident: 1513_CR22 publication-title: Int Immunol doi: 10.1093/intimm/dxs005 – volume: 63 start-page: 94 issue: 1 year: 2009 ident: 1513_CR192 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2008.04.001 – ident: 1513_CR117 – volume: 25 start-page: 5485 issue: 18 year: 2019 ident: 1513_CR55 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-0103 – volume: 6 start-page: 451 issue: 6 year: 2018 ident: 1513_CR71 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(18)30151-6 – volume: 468 start-page: 884 issue: 7326 year: 2010 ident: 1513_CR7 publication-title: Nature doi: 10.1038/468884a – volume: 8 start-page: 1 year: 2020 ident: 1513_CR17 publication-title: Cell Mol Immunol – volume: 1874 start-page: 188386 issue: 1 year: 2020 ident: 1513_CR45 publication-title: Biochim Biophys Acta Rev Cancer doi: 10.1016/j.bbcan.2020.188386 – volume: 3 start-page: e2025109 issue: 10 year: 2020 ident: 1513_CR149 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2020.25109 – volume: 11 start-page: 203636131986349 year: 2019 ident: 1513_CR8 publication-title: Rare Tumors doi: 10.1177/2036361319863498 – volume: 7 start-page: 201 issue: Suppl 1 year: 2019 ident: 1513_CR91 publication-title: J Immunother Cancer – ident: 1513_CR116 – volume: 26 start-page: 545 issue: 3 year: 2020 ident: 1513_CR189 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-2379 – volume: 181 start-page: 1383 issue: 12 year: 2010 ident: 1513_CR135 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200909-1465OC – volume: 8 start-page: 1 year: 2020 ident: 1513_CR138 publication-title: J Immunother Cancer doi: 10.1136/jitc-2019-000251 – volume: 21 start-page: 21 year: 2020 ident: 1513_CR118 publication-title: Int J Mol Sci doi: 10.3390/ijms21218305 – volume: 21 start-page: 1353 issue: 10 year: 2020 ident: 1513_CR63 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30445-9 – volume: 16 start-page: 11 year: 2021 ident: 1513_CR67 publication-title: J Thoracic Oncol doi: 10.1016/j.jtho.2021.01.323 – volume: 11 start-page: 187 year: 2013 ident: 1513_CR122 publication-title: J Transl Med doi: 10.1186/1479-5876-11-187 – volume: 37 start-page: 8549 issue: 15 year: 2019 ident: 1513_CR75 publication-title: J Clin Oncol doi: 10.1200/JCO.2019.37.15_suppl.8549 – volume: 6 start-page: 115 issue: 1 year: 2018 ident: 1513_CR93 publication-title: J Immunother Cancer – volume: 15 start-page: 16 year: 2020 ident: 1513_CR3 publication-title: J Occup Med Toxicol doi: 10.1186/s12995-020-00267-y – volume: 21 start-page: 430 issue: 3 year: 2012 ident: 1513_CR159 publication-title: Cancer Cell doi: 10.1016/j.ccr.2011.12.029 – volume: 10 start-page: 554570 year: 2020 ident: 1513_CR157 publication-title: Front Oncol doi: 10.3389/fonc.2020.554570 – ident: 1513_CR43 doi: 10.1158/1078-0432.CCR-18-2641 – volume: 33 start-page: 303 issue: 2 year: 2020 ident: 1513_CR89 publication-title: Mod Pathol doi: 10.1038/s41379-019-0364-z – volume: 17 start-page: 410 issue: 4 year: 2020 ident: 1513_CR114 publication-title: Cell Mol Immunol doi: 10.1038/s41423-019-0245-x – volume: 46 start-page: 211 issue: 5 year: 1990 ident: 1513_CR24 publication-title: Rev Pneumol Clin – ident: 1513_CR119 doi: 10.1016/j.ymthe.2020.10.023 – volume: 367 start-page: 6477 year: 2020 ident: 1513_CR188 publication-title: Science doi: 10.1126/science.aax0182 – volume: 22 start-page: 3791 issue: 15 year: 2016 ident: 1513_CR109 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-2133 – volume: 18 start-page: 562 issue: 9 year: 2020 ident: 1513_CR48 publication-title: Clin Adv Hematol Oncol – volume: 8 start-page: 1 year: 2020 ident: 1513_CR151 publication-title: J Immunother Cancer doi: 10.1136/jitc-2020-000713 – volume: 21 start-page: e9 issue: 1 year: 2020 ident: 1513_CR142 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30828-9 – ident: 1513_CR50 doi: 10.1016/j.cllc.2020.10.005 – volume: 6 start-page: 44892 issue: 42 year: 2015 ident: 1513_CR112 publication-title: Oncotarget doi: 10.18632/oncotarget.6285 – volume: 69 start-page: 402 issue: 5 year: 2019 ident: 1513_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21572 – volume: 9 start-page: 1169 issue: 4 year: 2020 ident: 1513_CR69 publication-title: Transl Lung Cancer Res doi: 10.21037/tlcr-19-686 – volume: 20 start-page: 2 year: 2019 ident: 1513_CR171 publication-title: Int J Mol Sci doi: 10.3390/ijms20020429 – volume: 20 start-page: 239 issue: 2 year: 2019 ident: 1513_CR70 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30765-4 – volume: 31 start-page: 1734 issue: 12 year: 2020 ident: 1513_CR58 publication-title: Ann Oncol doi: 10.1016/j.annonc.2020.09.009 – volume: 10 start-page: 126 year: 2020 ident: 1513_CR15 publication-title: Front Oncol doi: 10.3389/fonc.2020.00126 – volume: 30 start-page: 435 issue: 4 year: 2020 ident: 1513_CR39 publication-title: Thorac Surg Clin doi: 10.1016/j.thorsurg.2020.08.003 – volume: 9 start-page: S100 issue: Suppl 1 year: 2020 ident: 1513_CR47 publication-title: Transl Lung Cancer Res doi: 10.21037/tlcr.2019.11.23 – volume: 36 start-page: 847 issue: 9 year: 2018 ident: 1513_CR130 publication-title: Nat Biotechnol doi: 10.1038/nbt.4195 – volume: 74 start-page: 2460 issue: 9 year: 1994 ident: 1513_CR25 publication-title: Cancer doi: 10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N – volume: 9 start-page: 2909 year: 2018 ident: 1513_CR18 publication-title: Front Immunol doi: 10.3389/fimmu.2018.02909 – volume: 14 start-page: 878 issue: 3 year: 1996 ident: 1513_CR27 publication-title: J Clin Oncol doi: 10.1200/JCO.1996.14.3.878 – volume: 58 start-page: 1 issue: 1 year: 2020 ident: 1513_CR42 publication-title: Eur J Cardiothorac Surg doi: 10.1093/ejcts/ezaa158 – volume: 184 start-page: 1395 issue: 12 year: 2011 ident: 1513_CR110 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201103-0554CR – ident: 1513_CR95 doi: 10.1200/JCO.2020.38.15_suppl.3071 – volume: 13 start-page: 1655 issue: 11 year: 2018 ident: 1513_CR38 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.08.2036 – volume: 6 start-page: e1261241 issue: 1 year: 2017 ident: 1513_CR100 publication-title: Oncoimmunology doi: 10.1080/2162402X.2016.1261241 – volume: 393 start-page: 52 year: 2017 ident: 1513_CR124 publication-title: Cancer Lett doi: 10.1016/j.canlet.2017.02.015 – volume: 21 start-page: e10 issue: 1 year: 2020 ident: 1513_CR144 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30831-9 – volume: 18 start-page: 1261 issue: 9 year: 2017 ident: 1513_CR57 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30446-1 – volume: 19 start-page: 697 issue: 7 year: 2019 ident: 1513_CR19 publication-title: Expert Opin Biol Ther doi: 10.1080/14712598.2019.1606209 – volume: 16 start-page: 06 year: 2021 ident: 1513_CR68 publication-title: J Thoracic Oncol doi: 10.1016/j.jtho.2021.01.308 – volume: 21 start-page: 938 issue: 8 year: 2015 ident: 1513_CR105 publication-title: Nat Med doi: 10.1038/nm.3909 – volume: 39 start-page: 29 issue: 1 year: 2020 ident: 1513_CR164 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-020-1536-x – volume: 21 start-page: e8 issue: 1 year: 2020 ident: 1513_CR143 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30829-0 – volume: 8 start-page: 8 issue: 2 year: 2020 ident: 1513_CR31 publication-title: J Immunother Cancer doi: 10.1136/jitc-2020-001486 – volume: 12 start-page: 7 year: 2020 ident: 1513_CR127 publication-title: Cancers (Basel) doi: 10.3390/cancers12071826 – volume: 36 start-page: 1343 issue: 13 year: 2018 ident: 1513_CR11 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.76.6394 – volume: 14 start-page: 1207 issue: 6 year: 2020 ident: 1513_CR156 publication-title: Mol Oncol doi: 10.1002/1878-0261.12651 – volume: 24 start-page: 6345 issue: 24 year: 2018 ident: 1513_CR170 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-1231 – volume: 14 start-page: 1343 issue: 8 year: 2019 ident: 1513_CR40 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2019.04.029 – volume: 33 start-page: 180 issue: 2 year: 2009 ident: 1513_CR177 publication-title: Cell Biol Int doi: 10.1016/j.cellbi.2008.10.011 – volume: 48 start-page: 407 issue: 4 year: 2016 ident: 1513_CR148 publication-title: Nat Genet doi: 10.1038/ng.3520 – volume: 62 start-page: 103040 year: 2020 ident: 1513_CR74 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2020.103040 – volume: 13 start-page: S339 issue: 10 year: 2018 ident: 1513_CR64 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.08.277 – volume: 6 start-page: 149 issue: 1 year: 2018 ident: 1513_CR108 publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0454-3 – volume: 125 start-page: 1218 issue: 8 year: 2019 ident: 1513_CR186 publication-title: Cancer doi: 10.1002/cncr.31997 – volume: 12 start-page: S1089 issue: 1 year: 2017 ident: 1513_CR46 publication-title: J Thoracic Oncol doi: 10.1016/j.jtho.2016.11.1522 – volume: 34 start-page: 502 issue: 11 year: 2020 ident: 1513_CR54 publication-title: Oncology (Williston Park) – volume: 8 start-page: 114156 issue: 69 year: 2017 ident: 1513_CR162 publication-title: Oncotarget doi: 10.18632/oncotarget.23169 – volume: 8 start-page: 2 year: 2020 ident: 1513_CR101 publication-title: J Immunother Cancer doi: 10.1136/jitc-2020-000957 – volume: 121 start-page: 1921 issue: 6 year: 2002 ident: 1513_CR29 publication-title: Chest doi: 10.1378/chest.121.6.1921 – volume: 10 start-page: 1333 issue: 1 year: 2019 ident: 1513_CR155 publication-title: Nat Commun doi: 10.1038/s41467-019-09307-6 – volume: 136 start-page: 1180 issue: 4 year: 1971 ident: 1513_CR23 publication-title: Proc Soc Exp Biol Med doi: 10.3181/00379727-136-35454 – volume: 8 start-page: 342 issue: 3 year: 2020 ident: 1513_CR106 publication-title: J Immunother Cancer – volume: 10 start-page: 79 year: 2018 ident: 1513_CR165 publication-title: Clin Epigenet doi: 10.1186/s13148-018-0517-9 – volume: 21 start-page: 1213 issue: 9 year: 2020 ident: 1513_CR51 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30462-9 – volume: 6 start-page: 1610322 issue: 4 year: 2019 ident: 1513_CR154 publication-title: Mol Cell Oncol doi: 10.1080/23723556.2019.1610322 – volume: 223 start-page: 1 year: 2020 ident: 1513_CR176 publication-title: Immunol Lett doi: 10.1016/j.imlet.2020.04.002 – volume: 108 start-page: 13618 issue: 33 year: 2011 ident: 1513_CR5 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1105887108 – volume: 52 start-page: 9 year: 2016 ident: 1513_CR180 publication-title: Hum Pathol doi: 10.1016/j.humpath.2016.01.010 – volume: 41 start-page: 914 issue: 10 year: 2015 ident: 1513_CR80 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2015.09.006 – volume: 25 start-page: 389 issue: 3 year: 2019 ident: 1513_CR193 publication-title: Nat Med doi: 10.1038/s41591-019-0382-x – volume: 13 start-page: 2 year: 2021 ident: 1513_CR85 publication-title: Cancers (Basel) doi: 10.3390/cancers13020282 – volume: 193 start-page: 943 issue: 9 year: 2016 ident: 1513_CR136 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201512-2444ED – ident: 1513_CR173 doi: 10.2967/jnumed.120.250720 – volume: 9 start-page: 9 year: 2017 ident: 1513_CR125 publication-title: Cancers (Basel) doi: 10.3390/cancers9090115 – volume: 13 start-page: 1 year: 2019 ident: 1513_CR160 publication-title: Mol Ther Oncolytics doi: 10.1016/j.omto.2019.02.001 – ident: 1513_CR86 doi: 10.1200/JCO.2020.38.15_suppl.3004 – volume: 6 start-page: 261 issue: 261 year: 2014 ident: 1513_CR121 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3010162 – volume: 182 start-page: 5217 issue: 9 year: 2009 ident: 1513_CR179 publication-title: J Immunol doi: 10.4049/jimmunol.0803826 – volume: 19 start-page: 601 issue: 4 year: 2014 ident: 1513_CR191 publication-title: Int J Clin Oncol doi: 10.1007/s10147-013-0619-5 – volume: 13 start-page: 272 issue: 5 year: 2019 ident: 1513_CR20 publication-title: Clin Respir J doi: 10.1111/crj.13010 – volume: 13 start-page: 1569 issue: 10 year: 2018 ident: 1513_CR59 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.05.038 – volume: 15 start-page: 1409 issue: 9 year: 2020 ident: 1513_CR147 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2020.05.019 – volume: 4 start-page: 1038 issue: 12 year: 2016 ident: 1513_CR99 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-16-0171 – volume: 2 start-page: 393 issue: 5 year: 2014 ident: 1513_CR96 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-14-0039 – volume: 92 start-page: 650 issue: 3 year: 2001 ident: 1513_CR26 publication-title: Cancer doi: 10.1002/1097-0142(20010801)92:3<650::AID-CNCR1366>3.0.CO;2-0 – volume: 7 start-page: e1494111 issue: 10 year: 2018 ident: 1513_CR107 publication-title: Oncoimmunology doi: 10.1080/2162402X.2018.1494111 – volume: 8 start-page: 9 year: 2020 ident: 1513_CR128 publication-title: Oncogene – volume: 24 start-page: 2859 issue: 12 year: 2018 ident: 1513_CR37 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-3757 – ident: 1513_CR94 doi: 10.1111/pin.13028 – volume: 19 start-page: 649 issue: 8 year: 2017 ident: 1513_CR78 publication-title: Neoplasia doi: 10.1016/j.neo.2017.05.002 – volume: 8 start-page: 1 year: 2020 ident: 1513_CR98 publication-title: J Immunother Cancer doi: 10.1136/jitc-2020-000911 – ident: 1513_CR145 – volume: 150 start-page: 53 year: 2020 ident: 1513_CR153 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2020.09.026 – volume: 21 start-page: 2636 issue: 14 year: 2003 ident: 1513_CR12 publication-title: J Clin Oncol doi: 10.1200/JCO.2003.11.136 – volume: 24 start-page: 766 issue: 4 year: 2018 ident: 1513_CR137 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-2522 – volume: 20 start-page: 18 issue: 2 year: 2019 ident: 1513_CR66 publication-title: Curr Treat Options Oncol doi: 10.1007/s11864-019-0613-x – volume: 193 start-page: 1023 issue: 9 year: 2016 ident: 1513_CR132 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201508-1573OC – volume: 5 start-page: 653 issue: 7 year: 1994 ident: 1513_CR33 publication-title: Ann Oncol doi: 10.1093/oxfordjournals.annonc.a058941 – volume: 9 start-page: 166 issue: 2 year: 2007 ident: 1513_CR76 publication-title: Neoplasia doi: 10.1593/neo.07112 – ident: 1513_CR187 doi: 10.2967/jnumed.120.245803 – volume: 25 start-page: 2064 issue: 7 year: 2019 ident: 1513_CR167 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-3133 – volume: 20 start-page: 11 year: 2019 ident: 1513_CR182 publication-title: Int J Mol Sci doi: 10.3390/ijms20112674 – volume: 52 start-page: 189 issue: 2 year: 2006 ident: 1513_CR36 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2006.01.007 – volume: 5 start-page: 73 year: 1909 ident: 1513_CR16 publication-title: Ned Tijdschr Geneeskd – volume: 8 start-page: 89722 issue: 52 year: 2017 ident: 1513_CR81 publication-title: Oncotarget doi: 10.18632/oncotarget.21113 – volume: 4 start-page: 802 issue: 7 year: 2009 ident: 1513_CR178 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3181a8634d – volume: 74 start-page: 816 issue: 11 year: 2017 ident: 1513_CR10 publication-title: Occup Environ Med doi: 10.1136/oemed-2016-104173 – volume: 8 start-page: 280 issue: 3 year: 2019 ident: 1513_CR139 publication-title: Transl Lung Cancer Res doi: 10.21037/tlcr.2019.05.05 – volume: 33 start-page: 263 issue: 2 year: 2020 ident: 1513_CR88 publication-title: Mod Pathol doi: 10.1038/s41379-019-0328-3 – volume: 39 start-page: 147 year: 2019 ident: 1513_CR175 publication-title: Am Soc Clin Oncol Educ Book doi: 10.1200/EDBK_240837 – volume: 37 start-page: 318 issue: 4 year: 2019 ident: 1513_CR61 publication-title: J Clin Oncol doi: 10.1200/JCO.2018.78.2276 – ident: 1513_CR97 doi: 10.1080/14728222.2020.1841750 – volume: 38 start-page: 1007 issue: 9 year: 2020 ident: 1513_CR103 publication-title: Nat Biotechnol doi: 10.1038/s41587-020-0666-1 – volume: 23 start-page: 1920 issue: 8 year: 2017 ident: 1513_CR181 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-1741 – volume: 4 start-page: 628 issue: 8 year: 1997 ident: 1513_CR30 publication-title: Ann Surg Oncol doi: 10.1007/BF02303746 – ident: 1513_CR84 doi: 10.1200/JCO.2020.38.15_suppl.e15086 – volume: 4 start-page: 18 year: 2019 ident: 1513_CR169 publication-title: JCI Insight doi: 10.1172/jci.insight.128474 – volume: 5 start-page: 351 issue: 3 year: 2019 ident: 1513_CR60 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.5428 – volume: 8 start-page: 1069 issue: 9 year: 2018 ident: 1513_CR44 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-18-0367 – volume: 126 start-page: 3130 issue: 8 year: 2016 ident: 1513_CR131 publication-title: J Clin Invest doi: 10.1172/JCI83092 – volume: 3 start-page: 1375 issue: 12 year: 2015 ident: 1513_CR161 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-15-0077-T – volume: 34 start-page: 151 year: 2016 ident: 1513_CR104 publication-title: Annu Rev Immunol doi: 10.1146/annurev-immunol-041015-055435 – volume: 8 start-page: 1548 issue: 12 year: 2018 ident: 1513_CR87 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-18-0804 – ident: 1513_CR21 doi: 10.1016/j.ejcts.2006.11.046 – volume: 171 start-page: 1168 issue: 10 year: 2005 ident: 1513_CR134 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200501-057OC – volume: 70 start-page: 16 year: 2018 ident: 1513_CR183 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2018.07.006 – volume: 86 start-page: 1703 issue: 9 year: 2020 ident: 1513_CR194 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.14337 – volume: 226 start-page: 2595 issue: 10 year: 2011 ident: 1513_CR92 publication-title: J Cell Physiol doi: 10.1002/jcp.22600 – volume: 4 start-page: 2067 issue: 11 year: 2013 ident: 1513_CR158 publication-title: Oncotarget doi: 10.18632/oncotarget.1542 – volume: 15 start-page: 827 issue: 5 year: 2020 ident: 1513_CR113 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2019.12.128 – volume: 166 start-page: 1827 issue: 6 year: 2005 ident: 1513_CR77 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)62492-3 – ident: 1513_CR53 doi: 10.1016/S0140-6736(20)32714-8 – volume: 20 start-page: 1623 issue: 12 year: 2019 ident: 1513_CR141 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30642-4 – volume: 8 start-page: e1638211 issue: 9 year: 2019 ident: 1513_CR102 publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1638211 – volume: 227 start-page: 44 issue: 1 year: 2012 ident: 1513_CR6 publication-title: J Cell Physiol doi: 10.1002/jcp.22724 – volume: 8 start-page: 6 issue: 2 year: 2020 ident: 1513_CR79 publication-title: J Immunother Cancer doi: 10.1136/jitc-2020-001014 – volume: 108 start-page: 358 issue: 5 year: 2017 ident: 1513_CR9 publication-title: Med Lav – volume: 387 start-page: 1405 issue: 10026 year: 2016 ident: 1513_CR13 publication-title: Lancet doi: 10.1016/S0140-6736(15)01238-6 – volume: 9 start-page: 639 issue: 3 year: 2020 ident: 1513_CR195 publication-title: Transl Lung Cancer Res doi: 10.21037/tlcr-19-485 – volume: 23 start-page: 683 issue: 6 year: 1993 ident: 1513_CR28 publication-title: Aust N Z J Med doi: 10.1111/j.1445-5994.1993.tb04727.x – volume: 38 start-page: 9058 issue: 15 year: 2020 ident: 1513_CR168 publication-title: J Clin Oncol doi: 10.1200/JCO.2020.38.15_suppl.9058 – volume: 19 start-page: 552 issue: 2 year: 2020 ident: 1513_CR172 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-19-0356 |
| SSID | ssj0017853 |
| Score | 2.3748662 |
| SecondaryResourceType | review_article |
| Snippet | The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many... Background The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved... Abstract Background The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 148 |
| SubjectTerms | Antineoplastic Agents - therapeutic use Asbestos Cancer therapies Care and treatment Chemotherapy Clinical trials Clinical Trials as Topic Combined Modality Therapy CTLA-4 Antigen - antagonists & inhibitors CTLA-4 protein FDA approval Forecasts and trends Histology Humans Immune checkpoint inhibitors Immune system Immunotherapy Interferon Lung cancer Lung Neoplasms - therapy Mesothelioma Mesothelioma, Malignant - therapy Methods Non-small cell lung carcinoma Oncolysis Patients PD-1 protein Pleural diseases Pleural Neoplasms - therapy Programmed Cell Death 1 Ligand 2 Protein - antagonists & inhibitors Programmed Cell Death 1 Receptor - antagonists & inhibitors Pulmonology Rare diseases Response rates Review Small cell lung carcinoma Surgery Tumor necrosis factor-TNF Tumors |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1di9QwMOgJ4oucn1fvlAiCD1KuadK0eZJTPA5BnzzZt5BOk7Ow2663ew_-e2ey2XpFOChLu5OUZjKTmUnmg7F3RrVC6CLkhZcqV-Bkbirvc0c-USC60kD08v2uLy7V10W1SBtum-RWuV8T40LdjUB75KdlhaYBBU7qj-vfOVWNotPVVELjPntAqcvIpateTAYXFZ6X-0CZRp9uBJ2q5eSUgEJQyLyeCaOYs___lfmWaJq7Td6SQ-eH7HFSIPnZbsafsHt-eMoefktH5M_YT9pmospDnArF46t5P_CeokBSrNUfjnoqx3u-mlxf-BjwadlfkVsMXy89JePgK7-hPst-XLnn7PL8y4_PF3kqnpBDpeU2DwWEpgsS0AQQBciAzOnrBih7T4uAVprQgkFtCao6gA4Kf9sgis4ACFXLF-xgGAd_xLiBAKVyiLzaK9UFU3am1SjVutChticzJvZYtJAyi1OBi6WNFkaj7Q7zFjFvI-ZtnbEPU5_1Lq_Gna0_0eRMLSkndvxjvL6yicWsaTocShOATEzlhXOOMuFA4drCoSDO2HuaWkuci58HLgUg4CApB5Y9I1VFUuRwxk5mLZHjYA7eE4dNHL-x_-gzY28nMPUkL7bBjzexTanR4hb4ipc7WpqGJKVBqCwyVs-obDbmOWTof8V84A3F4pT61d2fdcwelZH0K7xO2MH2-sa_RoVq276JXPMX9YAfDA priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA_nCeKL-G31lAiCD1JtmjRtHkRO8TiE88mVewvpNDkL3fbc3QPvv3cm261XPHwSlrLbSUoznenMbGZ-w9gro2ohdBbSzEuVKnAyNYX3qaOcKBBNbiBm-X7Vxwv15bQ43WO7dkcjA9fXhnbUT2qx6t7--nn5ARX-fVT4Sr9bC9otSynZAI2bkGl5g91Ey1SSop6oP7sKJdqmXeHMtfNmxili-P_9pr5iquZplFfs0tFddmd0KPnhVgLusT3f32e3TsYt8wfsO_3tRJ2IODWOx0vztuctVYWMtVeXHP1Wjt_5ckqF4UPAX117Rmky_LzzBM7Bl35Nc7p2WLqHbHH0-dun43RsppBCoeUmDRmEqgkSMCQQGciAyurLCgjNp0ZCLU2owaD3BEUZQAeFxzqIrDEAQpXyEdvvh94_YdxAgFw5ZF7plWqCyRtTa7RyTWjQ-5MJEzsuWhiRxqnhRWdjxFFpu-W8Rc7byHlbJuzNNOd8i7Pxz9Ef6eFMIwkjO54YVmd2VDlrqgaXUgWgkFN54ZwjZBzIXJ05NMwJe02P1pJs4e2BGwsScJGEiWUPyXWRVEmcsIPZSNRAmJN3wmF3AmzzAm-aCn11wl5OZJpJWW29Hy7imFxjBC7wEo-3sjQtSUqDVJklrJxJ2WzNc0rf_oj44BXV5uT66f9g0jN2O48KUuDngO1vVhf-Obphm_pF1K3fjvcu_w priority: 102 providerName: Scholars Portal |
| Title | Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33952230 https://www.proquest.com/docview/2528957966 https://www.proquest.com/docview/2522621112 https://pubmed.ncbi.nlm.nih.gov/PMC8097826 https://doaj.org/article/98dc578fc01044e1aaa1564c0ab0a801 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9swED-2DsZexr7nrgsaDPYwTC1Llq3HdrSUQcsY68ibkM_SFkicsqQP--97ZzsmZrC9DIKJc5KQzne-U3T3O4D3VtdSmiymWVA61ehVaosQUs8xUSib3GIX5XtlLq7153kx3yv1xTFhPTxwz7hjWzVIUhWRNw46SO8945tg5uvMV33mFtm83WZqOD8oyQrtUmQqc7yRfJ6WcjgCmT-p0nJihjq0_j_fyXtGaRowuWeBzp_A48F1FCf9lJ_CvdA-g4eXw-H4c_jOfzBxzSHBJeJpaLFoxYLzP4Ysq9-CPFRB38VqDHoR60h3y8UPDogRN8vAMBxiFTbcZ7lYr_wLuD4_-_bpIh3KJqRYGLVNY4axaqJCcv5lhiqSWoayQsbtqYlQKxtrtOQnEWMjmqjpWkeZNRZR6lK9hIN23YbXICxGzLUn5pVB6ybavLG1IXvWxIb8PJWA3HHR4YApzqUtlq7bW1TG9Zx3xHnXcd6VCXwc-9z0iBp_bX3KD2dsyWjY3Q8kI26QEfcvGUngAz9axzpL00M_pB7QIhn9yp2wk6I4ZziBo0lL0jWcknfC4QZd37i8oElzSq9J4N1I5p4cv9aG9W3XJje015Y0xKtelsYlKWWJqrIEyomUTdY8pbSLnx0SeMVZOLk5_B9MegOP8k5BCvocwcH21214Sw7Xtp7B_XJezuDB6dnVl6-zTtPoeqmrO6f8KqQ |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1da9RAcKhXUF_Eb6NVV1B8kNBsdvOxDyKttlxte4i00rdtstmtgbvk7F2R_il_ozO5JDYIfSuEI7nZXbKzMzsz2fkAeKtkznkcOD-wQvrSZMJXkbV-Rj5RhhehMo2X7yQeH8uvJ9HJGvzpYmHIrbLbE5uNuqgNfSPfDCM0DShwMv40_-VT1Sg6Xe1KaKzIYt9e_kaTbfFx7wuu77sw3N05-jz226oCvolisfRdYFxaOGFQN-aBEQ6p1iapobQ2OQJyoVxuFKoRJkqciZ3E39zxoFDGcJkIHPcWrEuBpswI1rd3Jt--9-cWCUq_LjQnjTcXnM7xfHKDQLHLhZ8MxF9TJeB_WXBFGA4dNa9Ivt37cK9VWdnWisYewJqtHsLtw_ZQ_hH8oA9bVOuIUWl6HJqVFSsp7qSN7rpkqBkzvGez3tmG1Q6fpuUZOeKw-dRS-g82swvqMy3rWfYYjm8EsU9gVNWVfQZMGWdCmSHyEitl4VRYqDxGOVq4AvVL4QHvsKhNm8ucSmpMdWPTpLFeYV4j5nWDeZ148KHvM19l8ri29TYtTt-SsnA3f9TnZ7plaq3SAqeSOkNGrbQ8yzLKvWOCLA8yFP0evKel1bRX4OuZrA15wElS1i29RcqRoFhlDzYGLZHHzRDcEYdu95iF_scRHrzpwdST_OYqW180bcIYbXyOQzxd0VI_JSEUQkXgQTKgssGch5Cq_NlkIE8p-ieMn1__Wq_hzvjo8EAf7E32X8DdsGGDCK8NGC3PL-xLVOeW-auWhxic3jTb_gXLc17L |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Emerging+avenues+in+immunotherapy+for+the+management+of+malignant+pleural+mesothelioma&rft.jtitle=BMC+pulmonary+medicine&rft.au=Steven+G.+Gray&rft.date=2021-05-05&rft.pub=BMC&rft.eissn=1471-2466&rft.volume=21&rft.issue=1&rft.spage=1&rft.epage=24&rft_id=info:doi/10.1186%2Fs12890-021-01513-7&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_98dc578fc01044e1aaa1564c0ab0a801 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2466&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2466&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2466&client=summon |